Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Pharmacological evidence suggests that schizophrenia is associated with increased stimulation of dopamine (DA) D2 receptors. Recently, several groups have demonstrated that amphetamine-induced DA release is increased in schizophrenia, providing direct evidence for dysregulation of DA systems in this condition. In healthy volunteers, pretreatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine increases amphetamine-induced DA release to levels similar to those observed in patients with schizophrenia. Therefore, the dysregulation of DA function observed in schizophrenia might be secondary to NMDA hypofunction. In this study, the regulation of this response by glutamate (GLU) transmission was further characterized by using a metabotropic glutamate (mGlu) receptor group II agonist to inhibit GLU transmission. The amphetamine- (0.5 mg/kg intravenously (i.v.)) induced decrease in [11C]raclopride equilibrium-specific binding (V3'') was measured under control conditions and following pretreatment with the mGlu2/3 receptor agonist LY354740 (20 mg/kg i.v.) in four baboons. Amphetamine reduced [11C]raclopride V3'' by 28+/-7% under control conditions. Following LY354740 pretreatment, amphetamine-induced reduction in [11C]raclopride V3'' was significantly enhanced (35+/-7%, p=0.002). The enhancement of the amphetamine-induced reduction in [11C]raclopride V3'' by LY354740 was not a simple additive effect, as LY354740 alone did not reduce [11C]raclopride V3''. In conclusion, the results of this study further document the involvement of GLU transmission in regulating the effect of amphetamine-induced DA release, and provide additional support to the hypothesis that the dysregulation of DA function revealed by the amphetamine challenge in schizophrenia might stem from a deficit in GLU transmission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A method for the solution of certain non-linear problems in least squares
Levenberg, K. (1944) · Quarterly of Applied Mathematics · doi:10.1090/qam/10666 · Cited by 12,359
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Laruelle, 2003 ) and decreased glutamate (GLU) transmission at N -methyl- D -aspartate (NMDA) receptors (see, for reviews,”
BackgroundDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Rapid Automated Algorithm for Aligning and Reslicing PET Images
Woods, R. P., Cherry, S. R., & Mazziotta, J. C. (1992) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199207000-00024 · Cited by 1,912 · cited 1×
“PET images were coregistered to a volumetric T1-weighted magnetic resonance image (MRI) of the baboon's brain using an automated registration algorithm (”
MethodMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Ketamine blocks NMDA receptors, but also induces GLU release, resulting in the stimulation of other GLU receptors (”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 1×
“Three studies have reported an increase in amphetamine-induced DA release in patients with schizophrenia (”
BackgroundSelf-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Research works printed but not linked: 1
- Kim SE, Shin I, Oh SJ, Kim SH, Choe YS, Choi Y et al (1998). Nicotine-induced dopamine release evaluated with in vivo3H raclopride binding studies: comparison with in vivo dialysis data. J Nucl Med 39: 54P.
Cited by
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“…al., 2007; Saelens et al., 1980; Schiffer et al., 2006; Seneca et al., 2006; Sun et al., 2003; Tomic et al., 1997; Tomic and Joksimovic, 2000; van Berckel et al., 2006) and NE receptors (Finnema et al., 2015; Landau et al., 2012), which is an indirect indicator of increased competition for…”
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
From drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367
“This suggestion was confirmed in primates administered with amphetamine: PET showed that amphetamine-induced dopamine release was blocked by a metabotropic glutamate receptor agonist (van Berckel et al. 2006).”
BackgroundThe acute effects of NMDA antagonism: From the rodent to the human brain
Gunduz-Bruce, H. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.006 · Cited by 182
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Harrison, P., Lyon, L., Sartorius, L., Burnet, P., & Lane, T. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108089818 · Cited by 166
Glutamate signaling in the pathophysiology and therapy of schizophrenia
Lin, C., Lane, H., & Tsai, G. E. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.023 · Cited by 168
“Van Berckel et al. (2006) studied a mGluR2 agonist, LY354740 effect in four baboons.”
Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 94
Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers
Guo, N., Guo, W., Kralikova, M., Jiang, M., Schieren, I., Narendran, R., Slifstein, M., Abi-Dargham, A., Laruelle, M., Javitch, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.189 · Cited by 80
“…transmission in schizophrenia (Abi-Dargham et al , 2000; Breier et al , 1997; Laruelle et al , 1996) and substance abuse (Martinez et al , 2007; Volkow et al , 1997), as well as the effects of stimulants on DA neurotransmission (Kegeles et al , 2000; van Berckel et al , 2006; Volkow et al , 2009).”
Self-citationNeurophysiological and neurochemical animal models of schizophrenia: Focus on glutamate☆
Bickel, S., & Javitt, D. C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.05.005 · Cited by 66
An update on pharmacological approaches to neurodegenerative diseases
Scatena, R., Martorana, G. E., Bottoni, P., Botta, G., Pastore, P., & Giardina, B. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.1.59 · Cited by 66
“Motor neuron disease ONO-2506 II Astrocytic activation modulator and S-100 protein synthesis inhibitor [93]”
BackgroundVirdee, K., Cumming, P. D., Caprioli, D., Jupp, B., Rominger, A., Aigbirhio, F. I., Fryer, T. D., Riss, P. J., & Dalley, J. W. (2012) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.01.009 · Cited by 64
Role of metabotropic glutamate receptors in the control of neuroendocrine function
Durand, D., Pampillo, M., Caruso, C. M., & Lasaga, M. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.022 · Cited by 65
Neurosurgery for schizophrenia: an update on pathophysiology and a novel therapeutic target
Mikell, C. B., Sinha, S. R., & Sheth, S. A. (2015) · Journal of neurosurgery · doi:10.3171/2015.4.jns15120 · Cited by 56
Neuropathological changes in the substantia nigra in schizophrenia but not depression
Williams, M. R., Galvin, K., OSullivan, B., Macdonald, C., Ching, E. W.-K., Turkheimer, F., Howes, O. D., Pearce, R. K. B., Hirsch, S. R., & Maier, M. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0479-z · Cited by 59
Imaging Neurotransmitter Release by Drugs of Abuse
Martínez, D., & Narendran, R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_34 · Cited by 53
“…[11C]raclopride and an amphetamine challenge, one study showed that pretreatment with a metabotropic glutamate receptor group II agonist (which inhibits glutamate transmission) also increased dopamine release, similar to the effect seen with ketamine in human subjects (van Berckel et al. 2006).”
Self-citationHyperactivity of the dopaminergic system in NTS1 and NTS2 null mice
Liang, Y., Boules, M., Li, Z., Williams, K., Miura, T., Oliveros, A., & Richelson, E. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.015 · Cited by 53
“Thus, the increase in amphetamine-induced DA release in the NTS1 / mice may be a result of a deficiency in pre-synaptic glutamate control of DA neurotransmission (van Berckel et al., 2006).”
Pehrson, A. L., & Moghaddam, B. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1914-8 · Cited by 41
“In addition, a PET study in monkeys has reported that IV administration of 20.0 mg/kg of LY354740 increases amphetamineinduced [11C]raclopride displacement suggesting that, in contrast to the rodent microdialysis data, mGlu2/3 agonists increase dopamine release (van Berckel et al. 2006).”
InfluentialZhou, Y., Chen, M., Endres, C. J., Ye, W., Brašić, J. R., Alexander, M., Crabb, A. H., Guilarte, T. R., & Wong, D. F. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.06.038 · Cited by 42
“As listed in Table 6, paired bolus [11C]raclopride dynamic PET studies with arterial plasma input were commonly used in previous baboon amphetamine stimulation studies (Dewey et al., 1993; Drevets et al., 1999; Narendran et al., 2004; Price et al., 1998; van Berckel et al., 2005).”
InfluentialNeuroimaging and drug taking in primates
Murnane, K. S., & Howell, L. L. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2222-7 · Cited by 37
“Similarly, the mGluR2 agonist LY354740 potentiated amphetamine-elicited dopamine release , as measured by [ 11 C]-labeled raclopride (van Berckel et al. 2006).”
Tokunaga, M., Seneca, N. M., Shin, R.-M., Maeda, J., Obayashi, S., Okauchi, T., Nagai, Y., Zhang, M., Nakao, R., Ito, H., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.2559-08.2009 · Cited by 33
“…agonist LY354740, which was shown to modulate amphetamine-induced changes of [ 11C]raclopride binding in a PET study for anesthetized baboons (van Berckel et al., 2006), could also be assessable in animal models and humans by using our methodology with a feasible sensitivity to endogenous…”
MethodNonhuman Primate Positron Emission Tomography Neuroimaging in Drug Abuse Research
Howell, L. L., & Murnane, K. S. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136689 · Cited by 30
Dopamine partial agonist actions of the glutamate receptor agonists LY 354,740 and LY 379,268
Seeman, P. M., Caruso, C. M., & Lasaga, M. (2007) · Synapse · doi:10.1002/syn.20482 · Cited by 28
Neuroreceptor Imaging Studies in Schizophrenia
Frankle, G. W. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701679812 · Cited by 25
Neurochemical Imaging in Schizophrenia
Urban, N., & Abi‐Dargham, A. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_37 · Cited by 19
“…in the striatum, as evidenced by decreased [11C]raclopride BP after ketamine administration (Vollenweider et al. 2000), and potentiated the effect of amphetamine-induced DA release in healthy volunteers to levels similar to those observed in patients with schizophrenia (van Berckel et al. 2006).”
ResultLi, Z., Boules, M., Williams, K., Gordillo, A., Li, S., & Richelson, E. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.011 · Cited by 20
Imaging as Tool to Investigate Psychoses and Antipsychotics
Booij, J., & van Amelsvoort, T. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_12 · Cited by 16
The anatomy of co-morbid neuropsychiatric disorders based on cortico-limbic synaptic interactions
Totterdell, S. (2006) · Neurotoxicity Research · doi:10.1007/bf03033236 · Cited by 14
Østerbøg, T. B., On, D. M., Oliveras, I., Río-Álamos, C., Sánchez-González, A., Tapias-Espinosa, C., Tobeña, A., González‐Maeso, J., Fernández‐Teruel, A., & Aznar, S. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01829-w · Cited by 13
Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia
Kantrowitz, J. T., & Javitt, D. C. (2009) · Springer eBooks · doi:10.1007/978-0-387-30410-6_3 · Cited by 15
Laukkanen, V., Kärkkäinen, O. K., Kupila, J., Kautiainen, H., Tiihonen, J., & Storvik, M. (2014) · Alcohol and Alcoholism · doi:10.1093/alcalc/agu081 · Cited by 16
Gerdjikov, T. V., & Beninger, R. J. (2006) · BMC Neuroscience · doi:10.1186/1471-2202-7-43 · Cited by 14
“Group II mGluR agonists also modulate amphetamine-produced DA release, enhancing it in drug-naïve baboons [20] and impairing it in amphetamine-sensitized rats [21].”
BackgroundLi, Z., Liang, Y., Boules, M., Gordillo, A., & Richelson, E. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.016 · Cited by 10
“These observations are consistent with the idea that dysregulation of DA function revealed by amphetamine challenge in schizophrenia stems from a deficit in glutamate transmission (van Berckel et al., 2006).”
BackgroundInterventional Nuclear Brain Imaging
Leung, D. K.-W., & Heertum, R. L. V. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.12.004 · Cited by 5
Animal Models for Brain Research
Dam, D. V., & Deyn, P. P. D. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_1 · Cited by 3
Neurotransmitter visualization in schizophrenia
Brašić, J. R. (2013) · Journal of Biomedical Graphics and Computing · doi:10.5430/jbgc.v3n2p30 · Cited by 4
Tenback, D. E. (2006) · Research Publications (Maastricht University) · doi:10.26481/dis.20061025dt · Cited by 4
Animal Models for Brain Research
Dam, D. V., & Deyn, P. P. D. (2014) · Springer eBooks · doi:10.1007/978-3-642-42014-6_1 · Cited by 3
Functional Neuroimaging of the Acute Effects of Drugs of Abuse
Reed, L. J., & Nutt, D. J. (2011) · Wiley eBooks · doi:10.1002/9781119998938.ch4
Studying chemical and electrical neuronal dynamics as a platform for understanding schizophrenia
Das, T. K., Rajakumar, N., & Jog, M. (2013) · Journal of Coupled Systems and Multiscale Dynamics · doi:10.1166/jcsmd.2013.1029
Seeman, P. M., Caruso, C. M., & Lasaga, M. (2008)
PET studies on the mechanisms of action of antidepressant and antipsychotic drugs
Yang, K. (2017) · Figshare
Metadata
- Authors
- van Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M.
- Affiliations
- Columbia University (US)
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-21
- Volume
- 31
- Issue
- 5
- Pages
- 967-977
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2049064370
- Cited by
- 43
- References
- 70
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5k08mh001594-05, 5p30mh059342-02)
- National Institute of Mental Health (K02 MH01603, K02MH001603, MH59342-01, 1 K08 MH01594)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- amphetamine-induced dopamine release, group II metabotropic glutamate receptors, LY354740, glutamatergic neurotransmission, schizophrenia, ketamine, [11C]raclopride, D2 receptor binding, baboons, dopamine dysregulation
- MeSH terms
- Amphetamine, Animals, Bridged Bicyclo Compounds, Brain, Dopamine, Female, Male, Radioligand Assay, Schizophrenia, Dopamine Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2, Receptors, Metabotropic Glutamate, Dopamine Antagonists, Excitatory Amino Acid Agonists, Raclopride, Papio anubis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.